Atrasentan in Patients With Proteinuric Glomerular Diseases

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

July 2, 2024

Study Completion Date

October 27, 2026

Conditions
IgA NephropathyFocal Segmental GlomerulosclerosisAlport SyndromeDiabetic Kidney DiseaseDiabetic Nephropathy Type 2Immunoglobulin A Nephropathy
Interventions
DRUG

Atrasentan

Film-coated tablet

Trial Locations (33)

2065

Novartis Investigative Site, St Leonards

2250

Novartis Investigative Site, Gosford

3021

Novartis Investigative Site, St Albans

3073

Novartis Investigative Site, Reservoir

3168

Novartis Investigative Site, Clayton

4029

Novartis Investigative Site, Herston

14068

Novartis Investigative Site, Anyang-si

27004

Novartis Investigative Site, Lugo

27103

Brookview Hills Research Assoc, Winston-Salem

28009

Novartis Investigative Site, Madrid

28222

Novartis Investigative Site, Majadahonda

28801

Mountain Kidney And Hyper Associa, Asheville

46520

Novartis Investigative Site, Port de Sagunt

53226

Milwaukee Nephrologists SC, Wauwatosa

55455

Uni of Minnesota Hos and Clinics, Minneapolis

75246

Baylor Scott and White, Dallas

77054

Prolato Clinical Research Center, Houston

80230

Colorado Kidney Care, Denver

89146

DaVita Clinical Research, Las Vegas

90022

Academic Medical Research Institute, Los Angeles

91206

Kidney Disease Medical Group, Glendale

91773

North America Research Institute, San Dimas

94305

Stanford U School Of Medicine, Stanford

71101-4440

Northwest Louisiana Nephrology Research, Shreveport

02111

Tufts Medical Center, Boston

00165

Novartis Investigative Site, Roma

330-721

Novartis Investigative Site, Cheonan

02841

Novartis Investigative Site, Seoul

03722

Novartis Investigative Site, Seoul

134 727

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona

S10 2JF

Novartis Investigative Site, Sheffield

E1 1BB

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY